About
About Anhui Anke Biotechnology (Group) Co., Ltd
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits. In addition, it offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, essential liquids, and mouthwash; and sybthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, the company provides autosomal, sex chromosome, and other kits; paternity testing, tumor biological immunotherapy technology, and DNA testing services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab, an anti-VFDF product; ANKEBIO anti-PD1; and anti-covid19 products. The company was founded in 2000 and is based in Hefei, China.
Research context
Anhui Anke Biotechnology (Group) Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Anhui Anke Biotechnology (Group) Co., Ltd is currently in a long term uptrend where the price is trading 6.1% above its 200 day moving average.
From a valuation standpoint, the stock is 23.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 11.9.
Anhui Anke Biotechnology (Group) Co., Ltd's total revenue rose by 10.1% to $440M since the same quarter in the previous year.
Its net income has increased by 24.6% to $137M since the same quarter in the previous year.
Finally, its free cash flow grew by 44.7% to $51M since the same quarter in the previous year.
Based on the above factors, Anhui Anke Biotechnology (Group) Co., Ltd gets an overall score of 4/5.